BR112022014459A2 - Composição para avaliar um produto farmacêutico, métodos para avaliar a qualidade um produto farmacêutico, para analisar uma amostra e para medir um tempo de retenção de coluna de cromatografia, e, composto - Google Patents

Composição para avaliar um produto farmacêutico, métodos para avaliar a qualidade um produto farmacêutico, para analisar uma amostra e para medir um tempo de retenção de coluna de cromatografia, e, composto

Info

Publication number
BR112022014459A2
BR112022014459A2 BR112022014459A BR112022014459A BR112022014459A2 BR 112022014459 A2 BR112022014459 A2 BR 112022014459A2 BR 112022014459 A BR112022014459 A BR 112022014459A BR 112022014459 A BR112022014459 A BR 112022014459A BR 112022014459 A2 BR112022014459 A2 BR 112022014459A2
Authority
BR
Brazil
Prior art keywords
evaluate
pharmaceutical product
quality
compound
composition
Prior art date
Application number
BR112022014459A
Other languages
English (en)
Inventor
Un HWANG Jeong
Hwan Lee Kyu
Young Kim Eun
Kyoung Choi Su
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of BR112022014459A2 publication Critical patent/BR112022014459A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N2030/042—Standards
    • G01N2030/045—Standards internal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

COMPOSIÇÃO PARA AVALIAR UM PRODUTO FARMACÊUTICO, MÉTODOS PARA AVALIAR A QUALIDADE UM PRODUTO FARMACÊUTICO, PARA ANALISAR UMA AMOSTRA E PARA MEDIR UM TEMPO DE RETENÇÃO DE COLUNA DE CROMATOGRAFIA, E, COMPOSTO. A presente invenção provê uma substância relacionada de ácido (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-il)benziloxi)fenil)hex-4-inoico, e um método para avaliar a qualidade de ácido (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-il)benziloxi)fenil)hex-4-inoico usando o mesmo. De acordo com a presente invenção, é possível avaliar a qualidade e a estabilidade de uma composição farmacêutica compreendendo ácido (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-)8-il)benziloxi)fenil)hex-4-inoico usando um composto da fórmula 2 ou um sal do mesmo como padrão de referência.
BR112022014459A 2020-01-31 2021-01-29 Composição para avaliar um produto farmacêutico, métodos para avaliar a qualidade um produto farmacêutico, para analisar uma amostra e para medir um tempo de retenção de coluna de cromatografia, e, composto BR112022014459A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200012027A KR102270026B1 (ko) 2020-01-31 2020-01-31 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
PCT/KR2021/001191 WO2021154019A1 (ko) 2020-01-31 2021-01-29 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법

Publications (1)

Publication Number Publication Date
BR112022014459A2 true BR112022014459A2 (pt) 2022-09-13

Family

ID=76608058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014459A BR112022014459A2 (pt) 2020-01-31 2021-01-29 Composição para avaliar um produto farmacêutico, métodos para avaliar a qualidade um produto farmacêutico, para analisar uma amostra e para medir um tempo de retenção de coluna de cromatografia, e, composto

Country Status (10)

Country Link
US (1) US20230227465A1 (pt)
EP (1) EP4099010A4 (pt)
JP (1) JP7332816B2 (pt)
KR (1) KR102270026B1 (pt)
CN (1) CN115004024B (pt)
AU (1) AU2021214518B2 (pt)
BR (1) BR112022014459A2 (pt)
CA (1) CA3165381C (pt)
MX (1) MX2022009126A (pt)
WO (1) WO2021154019A1 (pt)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2407186C2 (de) * 1974-02-15 1983-08-11 Hoechst Ag, 6230 Frankfurt Neue, natürlich nicht vorkommende Analoga von Prostansäuren und Verfahren zu ihrer Herstellung, sowie diese Analoga von Prostansäuren enthaltende Arzneimittel
US4540690A (en) * 1982-02-09 1985-09-10 The Upjohn Company 2-(Phenylmethylene)cycloalkylamines and -azetidines
US4687800A (en) * 1985-10-11 1987-08-18 Ici Americas Inc. Tartrate-based light stabilizers for plastics
US5109691A (en) * 1989-12-08 1992-05-05 Research Corporation Technologies, Inc. Explosive detection screening system
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
AUPR110100A0 (en) * 2000-10-30 2000-11-23 Life Therapeutics Limited Improved separation of macromolecules
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
EP2160372A1 (en) 2007-06-15 2010-03-10 Medichem, S.A. Method for determining enantiomeric purity of darifenacin and intermediates
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CN103502325B (zh) * 2010-12-13 2016-08-10 塞特克技术公司 处理添加剂和其在旋转成型中的用途
KR101409847B1 (ko) * 2011-08-04 2014-06-27 현대약품 주식회사 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물
MX2015012456A (es) * 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN103360405B (zh) * 2013-05-24 2015-09-09 武汉工程大学 一种螺环化合物2,4,8,10-四羰基-3,9-二氧杂螺环[5,5]十一烷的合成方法
EP3071555A4 (en) * 2013-11-18 2017-05-31 Del Mar Pharmaceuticals Hplc analysis of impurities in dianhydrogalactitol
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AR102180A1 (es) * 2014-10-06 2017-02-08 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DK3207928T3 (da) 2014-10-17 2021-04-26 Hyundai Pharm Co Ltd Sammensat præparat, der indeholder hidtil ukendt 3-(4-(benzyloxy)phenyl)hex-4-inonsyrederivat og en anden aktiv bestanddel, til forebyggelse eller behandling af metaboliske sygdomme
SG11202004891PA (en) * 2017-12-01 2020-06-29 Hyundai Pharm Co Ltd Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Also Published As

Publication number Publication date
EP4099010A4 (en) 2024-02-28
CN115004024B (zh) 2024-04-26
CA3165381A1 (en) 2021-08-05
CA3165381C (en) 2024-03-05
AU2021214518A1 (en) 2022-08-25
EP4099010A1 (en) 2022-12-07
JP7332816B2 (ja) 2023-08-23
CN115004024A (zh) 2022-09-02
WO2021154019A1 (ko) 2021-08-05
JP2023512757A (ja) 2023-03-29
AU2021214518B2 (en) 2023-11-16
MX2022009126A (es) 2022-08-22
KR102270026B1 (ko) 2021-06-28
US20230227465A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
Andersson et al. Methylglyoxal evokes pain by stimulating TRPA1
Rook et al. Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents
Zhang et al. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment
Jones et al. Allosteric antagonism of insect odorant receptor ion channels
Li et al. An ICT-based fluorescent switch-on probe for hydrogen sulfide in living cells
More et al. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist
Dal Piaz et al. The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme
Bot et al. Cross-site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes
KR20010071696A (ko) 칼슘 채널 블록킹제
Fuller et al. CoREST complex-selective histone deacetylase inhibitors show prosynaptic effects and an improved safety profile to enable treatment of synaptopathies
Kamiński et al. Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl) ethyl] pyrrolidine-2, 5-diones
ATE479900T1 (de) Verfahren zur feststellung von oxidativem stress
Singh et al. Ketamine metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells
JP2007198829A (ja) 経血臭判定指標剤
CN101490007B (zh) 具有芷香酮亚结构的vr1香草素受体拮抗剂
EP3535414A1 (en) Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
Machleidt et al. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3
BR112022014459A2 (pt) Composição para avaliar um produto farmacêutico, métodos para avaliar a qualidade um produto farmacêutico, para analisar uma amostra e para medir um tempo de retenção de coluna de cromatografia, e, composto
Thysiadis et al. Design and synthesis of gallocyanine inhibitors of DKK1/LRP6 interactions for treatment of Alzheimer’s disease
Herédi et al. Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations
KR102133794B1 (ko) 세포 소기관 내 글루타치온 측정용 실시간 형광 이미징 센서 및 이의 제조 방법
Emery et al. CO2 relaxation of the rat lung parenchymal strip
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
Majewski et al. Accelerated barrier repair in human skin explants induced with a plant-derived PPAR-α activating complex via cooperative interactions
Jasek et al. Pharmacological characterization of ionotropic excitatory amino acid receptors in young and aged rat basal forebrain

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]